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Recent studies have found that severe surfactant dysfunction occurs during an asthma attack, but the changes in
surfactant in a guinea-pig model of chronic asthma have not been studied. We therefore analysed the surfactant
recovered from guinea-pigs after repeated inhalation of ovalbumin to see if the surfactant recovered from chronic
asthmatic lungs would be intrinsically altered. Guinea pigs immunized through repeated inhalation of aerosolized
ovalbumin (OA) were exposed to the antigen once a week for a month. Twenty-four hours after the last challenge
the alveolar wash was recovered. We calculated saturated phosphatidylcholine (Sat-PC) and total protein (TP) pool
sizes in alveolar spaces. Surfactant subtype conversion of large aggregate surfactant (LA) to small aggregate
surfactant was studied in vitro by means of the surface area cycling technique. The phospholipid composition of LA
was analysed by thin layer chromatography and the surface activity of LA was also determined. We found
decreased surfactant pool sizes, decreased ratio of Sat-PC to TP in alveolar lavages in asthma groups, and surface
activity of the surfactant recovered from asthmatic lungs to be inferior to that of the controls. Accelerated
surfactant subtype conversion in vitro was also noted in the lungs of asthmatic animal models. In addition, the
changes in phospholipid compositions which were similar to the pattern of acute lung injury suggested that alveolar
inflammation might be involved in the pathogenesis of chronic asthma. These results indicate that surfactant is
intrinsically abnormal in chronically asthmatic lungs.
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Although numerous previous studies have revealed that
bronchial asthma is an inflammatory disease of the airway,
the pathogenesis of asthma has not been understood
completely. Evidence from autopsy studies suggests that
the pathological changes seen in asthma occur in both the
large and small airways (1). Hamid et al. also studied the
small airways and parenchyma of resected lung specimens
from patients with asthma and demonstrated that there was
a similar but more severe inflammatory process present in
the peripheral compared with the central airways of
patients with asthma (2). Recent physiological evidences
also suggest that the peripheral airways are the major site of
airway obstruction and account for the majority of the
airway hyper-responsiveness in patients with asthma (3,4).Received 24 February 2000 and accepted in revised form 13
November 2000.
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0954-6111/01/030180+07 $35?00/0Pulmonary surfactant is a highly surface active material
which is mainly synthesized by alveolar type II cells and
prevents alveolar collapse by reducing surface tensions at
the air–liquid interface. Surfactant also covers the surface
of small airways and plays a significant role in the patency
of small airways (5–7). Kurashima et al. (8) first reported in
adult asthmatics that nebulization of surfactant-TA
resulted in dramatic improvement of vital capacity (VC)
and forced expiratory volume in 1 sec (FEV1), suggesting
surfactant dysfunction in the asthmatic lungs. Recently, Liu
et al. demonstrated that a rapid inactivation of surfactant
developed within 30min when the intra-muscularly im-
munized guinea-pig was challenged with antigen (9). They
found a similar phospholipid concentration and composi-
tion in immunized and challenged animals and controls,
and speculated that severe surfactant dysfunction could be
due to the proteins leaked into the airways.
More recently, Kurashima et al. analysed surface activity
of sputum from acute asthmatic patients and demonstrated
that surface properties of airway fluid deteriorated in the
early phase of the asthma attack, but were ameliorated in
the recovery phase, which suggested that changes in airway
surfactant may be partly involved in the pathogenesis of# 2001 HARCOURT PUBLISHERS LTD
SURFACTANT CHANGES IN BRONCHIAL ASTHMA 181airway obstruction during an asthmatic attack (10). The
changes of surfactant in patients or animal models of
chronic asthma however, has not been studied extensively.
We previously reported that guinea-pigs sensitized by
repeated inhalation of ovalbumin (OA) aerosols exhibited
not only prolonged two-peaked eosinophil infiltration in
the airway (6 and 24 h after the antigen challenge), but also
late-phase airway narrowing and post-late-phase airway
hyper-responsiveness, similar to the asthmatic response in
human atopic asthma (11,12). In the present study, we
therefore analysed surfactant recovered from lungs in
guinea-pigs following repeated inhalation of ovalbumin to





This study protocol was reviewed and approved by the
Dokkyo University School of Medicine Committee on
Animal Care, and complies with NIH guidelines for animal
care. Female Hartley guinea-pigs ranging in weight from
250 to 300 g were sensitized by exposure to an aerosol of
OA solution (1% in sterile saline) for 10min a day for 10
consecutive days as described previously (11,12). A selective
H1 antagonist, d,1-chlorpheniramine maleate (10mg kg71)
was administrated intra-peritoneally 15min before the OA
inhalation to avoid fatal anaphylactic reaction from day 6.
Seven days after the end of the 10-day exposure of the
antigen, the animals were subjected to antigen inhalation
and the antigen inhalation was repeated every 7 days.
EXPERIMENTAL PROTOCOLS
Guinea-pigs were divided into four separate groups as
follows (Fig. 1):
(i) immunized with OA exposure and challenged with
OA (OA-OA);
(ii) immunized with OA and ‘challenged’ with saline;
(OA-S);
(iii) ‘immunized’ with saline and ‘challenged’ with
OA (S-OA);
(iv) ‘immunized’ with saline and ‘challenged’ with sal-
ine (S-S).
At day 45, the guinea-pigs were placed in an acrylic cylinder
which completely covered their heads. Then, through theFIG 1. Experimental protocols.cylinder, they were exposed to an aerosol of 1% OA or
saline for 1min using a DeVilbiss 646 nebulizer (DeVilbiss
Co, Somerset, PA, U.S.A.) driven by compressed air at
5 lmin71. Respiratory resistance (Rrs) was measured by a
modification of a forced oscillation technique described by
Mead (13) in inhalation-sensitized guinea-pigs and the
animals that failed to develop more than 100% increase of
baseline Rrs immediately after the challenge were excluded
from this study. Twenty-four hours after the challenge,
each animal was killed by intraperitoneal injection of
pentobarbital (100mg kg71 body weight) followed by
transection of the abdominal aorta.
ISOLATION OF SURFACTANT
After opening the thorax completely, the animal was
tracheostomized and lavaged with saline at 48C as reported
previously (14,15). The eciency for recovery of surfactant
by the lavage procedure was evaluated by separately
analysing eight sequential lavages.
Surfactant in alveolar washes was separated into large
and small aggregate surfactants by centrifugation (14,15).
Briefly, the pooled alveolar washes for each animal were
first centrifuged at 140 g for 10min to remove cell debris.
The recovered cells were analysed on total and differential
cell counts. The supernatant was then centrifuged at
40 000 g for 15min at 48C. The pellet from the 40 000 g
centrifugation was suspended in saline and layered over
0?8M sucrose in saline. After centrifugation at 40 000 g for
15min, the pellicle floating on the sucrose solution was
aspirated and recentrifuged at the same g force for 15min.
Recovered surfactant as the pellet was designated as large
aggregate surfactant (LA) and suspended in 0?1–0?2ml of
saline. The supernatant from the first 40 000 g centrifuga-
tion was designated as small aggregate surfactant (SA).
Large aggregate surfactant isolated from three guinea-pigs
was combined for the measurement of surfactant subtype
conversion, minimal surface tension and phospholipid
composition because of the small surfactant pool sizes.
SURFACTANT ANALYSIS
To determine the saturated phosphatidylcholine (Sat-PC)
pool size, aliquots of alveolar washes were extracted with
organic solvent (16) and treated with osmium tetroxide
(17), and the quantity of Sat-PC recovered from alumina
columns was measured by phosphorus assay (18). The
amount of total protein was measured by the method of
Lowry et al. (19). Phospholipid compositions of lipid
extracted samples of large aggregate surfactant recovered
from animals were determined by two dimensional thin-
layer chromatography (20).
SURFACTANT SUBTYPE CONVERSION IN
VITRO
Surface area cycling was performed as described previously
(14,21–23). Briefly, an aliquot of LA isolated from each
182 G. CHENG ET AL.group of animals was resuspended in Tris buffer (0?15M
NaCl, 0.01M Tris HCl, 1mM CaCl2, 1mM MgSO4 and 0?1
mM EDTA at pH 7?4). Each LA (0?5mg as total lipids) was
mixed with 2ml of Tris buffer in a capped polystyrene tube
(Becton Dickinson, Lincoln Park, NJ, U.S.A.). The
polystyrene tubes were attached to the disk of a Rototorque
rotator (TAITEC, Japan). The tubes were then rotated for
3 h at 40 rpm at 378C in order to increase the surface area
from 1?1 to 9?0 cm2 twice in each cycle. The contents of
tubes were centrifuged at 40 000 g for 15min at 48C. The
quality of LA in the pellet and the residual SA in the
supernatants converted from LA were measured by
phosphorous assay of lipid extracts (16,19).
MINIMAL SURFACE TENSION
MEASUREMENTS
The large aggregate surfactants (LA) have good surface
activities when tested in vitro are functional as surfactant
when tested in vivo (23). Large aggregate surface activities
were tested in this study. A pulsating bubble surfactometer
(PBS, Electronetics, Amherst, NY, U.S.A.) was used for
minimal tension measurements (24). The concentrations of
LA were adjusted to 1?25 or 2?5mg of lipids per milliliter
and applied to the measurements. The bubble pulsates
at a rate of 20 cycles min71 and the value at minimal
bubble size (STmin) during 15min of pulsation was
assessed.
DATA ANALYSIS
All values are expressed as means+SEM. The significance
of differences between means of the groups were tested
by analysis of variance with the Bonferroni correction.
P-values less than 0?05 were considered to indicate













484+8 7?9+1?3* 32?0+2?2* 17?3+1?4*
OA-SAL
(n=15)
473+8 5?8+0?7* 20?0+2?1* 2?3+0?5
SAL-OA
(n=15)
490+16 2?3+0?3 5?0+0?9 3?0+1?0
SAL-SAL
(n=15)
482+17 2?2+0?5 4?0+1?0 3?0+1?8
Value are means +SEM.
*P50?01 OA-OA, OA-SAL vs.SAL-OA, SAL-SAL;
**P50?01 OA-OA vs.OA-SAL, SAL-OA, SAL-SAL.Results
DESCRIPTION OF ANIMALS AND
RECOVERED CELL FRACTIONS IN BAL
FLUIDS
The bronchial lavage (BAL) fluid from animals in the OA-
OA and OA-S groups contained increased total cells,
eosinophils and neutrophils compared with those from
control animals (OA-OA, OA-S vs. S-OA, S-S, P50?01;
Table 1). The alveolar washes recovered from OA-OA
animals also contained a higher percentage eosinophils and
neutrophils than those from OA-S (P50?01).
ALVEOLAR WASHES AND POOL SIZES
To quantify the surfactant pool sizes in asthmatic animals,
alveolar lavage technique is critical. We were concerned
whether surfactant could be recovered consistently by
alveolar washes from an animal model of bronchial asthma.
Therefore, eight sequential alveolar washes from the
animals in four studied groups were analysed separately
for Sat-PC content (data not shown). The shapes of the
washout curves were similar in OA-immunized and non-
immunized guinea-pigs, indicating that the alveolar wash
procedure was similarly effective for animals in all groups.
For all subsequent results with alveolar washes, five
repetitive washes were performed and pooled as reported
previously (14,15).
Alveolar Sat-PC pools in OA-OA and OA-S animals
were significantly smaller than those in S-OA and S-S
animals (P50?01, Table 2). Alveolar LA pools in OA-OA,
OA-S groups were also smaller than those in S-OA and S-S
groups [P50?01, Fig. 2(b)]. Per cent LA was similar in all
four groups [Fig. 2(a)]. Total protein contents in alveolar
washes was increased four-fold in the OA-OA group, and
two-fold in the OA-S group relative to the non-immunized
group (OA-OA4OA-S4S-OA, S-S, P50?001, Table 2).
The ratios of Sat-Pc to total protein contents were also
smaller in asthma groups than those in control groups (OA-
OA4OA-S4S-OA, S-S, P50?01, Table 2).TABLE 2. Surfactant analysis






OA-OA 3?85+0?2* 20?7+2?7** 0?224+0?12*
OA-SAL 4?00+0?2* 10?9+1?3* 0?437+0?206*
SAL-OA 4?44+0?2 4?8+0?4 1?062+0?265
SAL-SAL 4?56+0?5 4?3+0?5 1?176+0?505
Value are means +SEM (n=5).
*P50?01 OA-OA, OA-SAL vs. SAL-OA, SAL-SAL;
**P50?001 OA-OA vs.OA-SAL, SAL-OA, SAL-SAL.
SAT-PC: saturated phosphatidylcholine; TP: total protein;
AW:alveolar wash.
FIG 2. Per cent large aggregate forms (LA) of surfactant
(a), LA pool sizes in the alveolar lavages (b), and
surfactant subtype conversion from LA to small aggregate
forms in vitro (c). Alveolar lavages recovered from OA-
OA, OA-S groups contained significantly less LA than did
those from S-OA, S-S groups (n=15 for each group,
P50?01). Per cent LA was similar in four groups. Cycling
for 180min resulted in about 45% conversion of the large
aggregate forms from OA-immunized guinea-pigs but
only *38% of the surfactant from non-immunized
animals converted to small aggregate forms (n=5 for each
measurement. P50?01, OA-OA, OA-S4S-OA, S-S).
Values are expressed as means+SEM.
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VITRO
Cycling for 180min resulted in about 45% conversion
of the LA from OA-immunized guinea-pigs but only
*38% of the surfactant from non-immunized animals
converted to SA [OA-OA, OA-S4 S-OA, S-S, P50?01,
Fig. 2(c)].PHOSPHOLIPID COMPOSITION
The phospholipids recovered by alveolar wash from OA-
OA and OA-S animals contained a lower proportion of
phosphatidylcholine, phosphatidylglycerol and a higher
proportion of phosphatidylinositol, than did the S-OA,
S-S animals (P50?01, Table 3). A proportion of lysopho-
sphatidylcholine in asthmatic animals tended to be higher
than that in controls. The compositions of the phospholi-
pids for OA-OA, and OA-S guinea-pigs were very similar.
These patterns of phsopholipid compositions in asthmatic
animals were quite similar to those seen in animal models in
acute lung injury (25).
SURFACE TENSION MEASUREMENTS
The mean minimal surface tension of LA recovered from
asthmatic and control animals are shown in Fig. 3.
Although the mean minimal surface tensions at
2?5mgml71 lipids were not different between the surfactant
recovered from OA-OA and OA-S and that from S-OA and
S-S groups, the animals in the OA-OA and OA-S groups
showed significantly higher minimal surface tensions at 1?25
mgml71 lipid than did the S-OA and S-S animals
(P50?01).
Discussion
We found decreased surfactant pool sizes and the ratio of
Sat-PC to total protein in alveolar washes in asthmatic
animals compared with those in controls. Since leaked
serum proteins can inhibit surfactant function directly
(15,26), it is probable that surfactant dysfunction could
occur in the lungs of the asthmatic animal models. The
surface activity for the surfactant recovered from the
asthmatic animals were also inferior to those from control
animals in our study. Therefore, the increased leaked
proteins, decreased surfactant pool size and the inferior
surface activity of the surfactant itself could further limit
surfactant function in the asthmatic lungs. Pulmonary
surfactant is not only important for the stability of the
alveoli, but also for small airway function (5–7). The
patency of small airway could be dependent on the
properties of surfactant (6,7). The surfactant film at the
alveolar air/liquid interface is partly extruded into adjacent
conducting airways during expiration. The extruded
dysfunctional surfactant would result in the airway closure
which is often seen in asthmatic lungs (27).
One possible explanation for the decreased surfactant
pool size in asthma groups could be due to the increased
phospholipases. Increased levels of phospholipase A2 have
been found in BAL fluids from patients with bronchial
asthma (28). The enzyme catalyses the hydrolysis of
phospholipids in membranes of epithelial cells. Moreover,
surfactant phospholipids could be catalysed into lysopho-
sphatidylcholine and palmitic acid by phospholipase A2.
Superoxides, proteinases from eosinophils, like myeloper-
oxidase, eosinophil cationic proteins which are abundant in
TABLE 3. Phospholipid composition of pulmonary surfactant (% of total phospholipid)
Groups PC PG PI PE LPC SM PS
OA-OA 77?6+1?3* 8?0+0?3* 8?4+0?9* 3?4+0?1 1?1+0?2 0?9+0?1 0?8+0?2
OA-SAL 76?4+1?1* 8?2+0?2* 8?6+0?3* 3?6+0?4 1?2+0?1 1?0+0?2 0?9+0?2
SAL-OA 80?4+0?6 9?6+0?3 3?9+0?3 3?5+0?2 0?8+0?1 1?2+0?1 0?8+0?1
SAL-SAL 80?9+0?4 9?8+0?2 3?9+0?3 3?4+0?2 0?8+0?1 1?1+0?1 0?8+0?1
Value are means +SEM (n=5).
*P50?01 OA-OA, OA-SAL vs. SAL-OA, SAL-SAL.
PC: phosphatidylcholine: PG: phosphatidylglycerol; PI: phosphatidylinositol; PE: phosphatidylethanolamine: LPC:
lysophosphatidylcholine; SM: sphyngomyelin; PS: phosphatidylserine.
FIG 3. Minimal surface tension of surfactant recovered
from asthmatic and control animals. Although the mean
minimal surface tensions at 2?5mgml71 lipids were not
different between OA-OA and OA-S groups and S-S and
S-OA groups, surfactant from animals in OA-OA and
OA-S groups showed significantly higher minimal surface
tensions at 1?25mgml71 lipid than in S-S and S-OA
groups (n=5 for each measurements; P50?01).
&: 1?25 mg71 lipid; &: 2?5mgml71 lipid.
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damage the surfactant.
Surfactant exists mainly in two general subtypes: LA
composed of lamellar bodies, tubular myelin and loose lipid
arrays that has good biophysical and in vivo function, and
SA in vesicular forms with poor function (5–7). LA is a
newly secreted material from type II cells and is thought to
be a source of the surface films at the air–liquid interface
(29). This film is then refined to increase the concentration
of Sat-PC through changes in surface area with breathing,
and then small vesicles, primarily containing lipids, re-enter
the hypophase for recycling or catabolism. The conversion
of surfactant from LA to SA can be also reproduced in vitro
by using a surface area cycling technique (22,30). The
converted SA in vitro does not function as surfactant in vivo
or in vitro (23). Using this technique, Gross et al. (22,31)
studied the conversion from LA to SA in vitro. Ueda et al.
previously reported that the rate of in vitro conversion of
LA to SA was more rapid for surfactant for preterm
animals than from surfactant from mature or adult animalsin sheep (32). The rate of the conversion also increased
when the LA were recovered from animals with lung injury
(21). The rate of form conversion is now thought to be
one of the factors governing the size of functional
surfactant pools in the lungs. We also found increased
surfactant subtype conversion for the surfactant recovered
from the animals in asthma groups compared with the
surfactant from controls. The accelerated surfactant sub-
type conversion would be the another explanation for
the decreased functional surfactant pool sizes in the
asthmatic lungs.
The rate of in vitro conversion of LA to SA is regulated
by multiple factors. Conversion is more rapid for LA from
humans and animals with lung injury (15,27). Ventilation
style could also affect the form conversion in preterm lambs
and a rabbit model of acute lung injury (33,34). The
conversion is thought to be mediated by a serine protease,
referred to ‘surfactant convertase’ (22). Recently, Gross
et al. proposed that the surfactant convertase is a
carboxylesterase (35). The conversion of LA to SA is
inhibited by SP-A (21,36). Veldhuizen et al. found that SP-
B was degraded during the conversion from LA to SA (37),
suggesting that SP-B may be the substrate for ‘surfactant
convertase’. We do not have the accurate assays for SP-A,
SP-B and ‘convertase’ in the BAL fluids of guinea-pigs, but
we also demonstrated the elevated minimal surface tension
for the surfactant recovered from asthmatic animals. Taken
together, compositional changes, i.e. decreased SP-A and
SP-B, or increased ‘convertase’ activity could exist in the
surfactant system for asthmatic lungs.
In our study, the accelerated conversion rate in asthma
models did not reflect the percentage of LA in vivo as
several studies have reported before in acute lung injury
(20,25,31). For example, there was a five-fold increase in the
ratio of SA to LA in N-nitroso-N-methylurethane-injured
rabbits due to the more rapid surfactant subtype conver-
sion. The explanation for this discrepancy might be due to
the differences of the degree of the lung injury. If the
recycling or catabolic pathway (i.e. type II cells) is not
damaged severely in acute lung injury, the accumulation of
non-functional surfactant could not occur.
Liu et al. recently reported surfactant dysfunction when
the immunized guinea-pig was challenged with
OA (9). Although they could not find any changes in
SURFACTANT CHANGES IN BRONCHIAL ASTHMA 185surfactant composition and concentration in the asthmatic
animals killed 30min after challenge, they clearly showed
the correlation between the minimal surface tension of
concentrated BAL and the ratio of proteins to phospholi-
pids, and they speculated that proteins leaking into airways
inhibited the surfactant function in the acute phase of an
asthma attack. In the present study, we would like to focus
on the changes of surfactant in ongoing, chronic asthma.
Therefore, we used the inhalation-sensitized model to study
the surfactant properties. The guinea-pigs sensitized by
repeated inhalation of OA aerosols exhibit two-peaked
eosinophil infiltration at 6 h and 24 h after antigen challenge
in the airway, late-phase airway narrowing and airway
hyper-responsiveness, similar to the asthmatic response in
human atopic asthma (11,12). Moreover, the animal models
showed the airway wall thickening similar to the remodelled
airway in humans if the animals were exposed to antigen
(OA) repeatedly up to 24 weeks (38), although we did not
find significant airwall thickening during 4 weeks exposure
to OA in the previous study (38). We also studied two
groups of asthmatic animals, in OA-OA and OA-S groups.
The alveolar lavages from the OA-OA group contained
significantly increased eosinophils and neutrophils than
those from the OA-S group, which means the lungs of
animals in OA-OA group remained the influence of
acute phase reaction even 24 h after the challenge.
However, we could not detect any significant alterations
of surfactant properties between the animals in OA-OA
and OA-S groups. These results suggests that we are
looking at the chronic changes of surfactant in the animal
models.
A particularly intriguing result is the observation that the
altered phospholipid compositions in asthma models, which
were similar to those seen in acute lung injury, although the
degree of change seemed to be moderate (25). Recently,
Kraft et al. studied chronic asthma patients with/without
nocturnal asthma by comparing proximal airway endo-
bronchial tissue with distal alveolar tissue and they found
that eosinophils and macrophages accumulated to a greater
extent in the alveolar tissue and that these changes
contribute more to the variation in lung function compared
with inflammation in the more proximal tissue (39). Recent
autopsy studies (1) also suggest that the pathological
changes seen in asthma occur in the airways as well as the
alveolar area. The altered phospholipid composition in our
study could result from the inflammation in type II cells.
Further studies regarding the involvement of alveolar
inflammation in the pathogenesis of bronchial asthma are
needed.
In summary, we demonstrated the intrinsic changes of
surfactant in the asthmatic lungs. Surfactant pool size
decreased and surface activity of surfactant itself recovered
from asthmatic lungs was inferior to that of surfactant from
controls. Accelerated subtype conversion in vitro also
suggested compositional changes of surfactant. The
changes of phospholipid compositions also suggested the
alveolar inflammation. Further studies to clarify the
pathogenesis of these intrinsic changes of surfactant will
be needed to understand the mechanisms of ‘airway and
alveolar inflammation’ in bronchial asthma.Acknowledgements
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